CATHEREX
In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.
In April 2010, Medigene assigned its development program of oncolytic (cancer-killing) herpes simplex viruses (oHSV), to Catherex, Inc.